HP
CNCE

Hikari Power’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Hikari Power’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,743
Closed -$200K – 103
2017
Q1 		$200K Buy
+11,743
New +$141K 0.03% 63

Other funds holding CNCE

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM

Hikari Power's CNCE Position: Q2 2017 in Review

Hikari Power sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2017, closing a stake of 11,743 shares — an estimated $200K sold.

Hikari Power first reported a position in CNCE in Q1 2017 and held it in 1 quarter. The position peaked at $200K in Q1 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q2 2017.

  • Hikari Power reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Hikari Power sold 11,743 Concert Pharmaceuticals, Inc. shares in Q2 2017, an estimated $200K.
  • Hikari Power first reported a position in Concert Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • Hikari Power's Concert Pharmaceuticals, Inc. position peaked at $200K in Q1 2017.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2017.

Based on Hikari Power's 13F filing for Q2 2017, filed 9 Aug 2017.